Although further study is warranted, these findings suggest that the reduction of GPNMB expression in serum reflects not only neuronal protection but also hepatic improvement of NPC manifestations during the intracerebroventricular administration of HP-β-CD. The gene discussed is GPNMB; the disease is nasopharyngeal carcinoma.